Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis
European Heart Journal - Cardiovascular Pharmacotherapy · 08.02.2025 · 11 (1) · 10-19
DOI: 10.1093/ehjcvp/pvae074 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 08.10.2024. Verfasst von Bertram Pitt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypokalemia, Mineralocorticoid Receptor Antagonists, Naphthyridines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer AG, Fidelity.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Hypokalaemia is associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). This exploratory FIDELITY analysis, a prespecified pooled patient-dataset from FIDELIO-DKD and FIGARO-DKD, investigated the incidence and effect of hypokalaemia in patients with CKD and type 2 diabetes (T2D) treated with finerenone vs. placebo. Methods and results Outcomes include the incidence of treatment-emergent hypokalaemia (serum potassium <4.0 or <3.5 mmol/L) and the effect of finerenone on cardiovascular composite outcome (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure) and arrhythmia composite outcome (new diagnosis of atrial fibrillation/atrial flutter, hospitalization due to arrhythmia, or sudden cardiac death) by baseline serum potassium subgroups. In the FIDELITY population, treatment-emergent hypokalaemia with serum potassium <4.0 and <3.5 mmol/L occurred in 41.1% and 7.5%, respectively. Hazards of cardiovascular and arrhythmia composite outcomes were higher in patients with baseline serum potassium <4.0 vs. 4.0–4.5 mmol/L [hazard ratio (HR) 1.16; 95% confidence interval (CI) 1.02–1.32, P = 0.022 and HR 1.20; 95% CI 1.00–1.44, P = 0.055, respectively]. Finerenone reduced the incidence of hypokalaemia with serum potassium <4.0 mmol/L (HR 0.63; 95% CI 0.60–0.66) and <3.5 mmol/L (HR 0.46; 95% CI 0.40–0.53) vs. placebo. Finerenone lessened the hazard of cardiovascular and arrhythmia events vs. placebo, irrespective of baseline serum potassium.
Conclusion
A substantial proportion of patients with CKD and T2D experienced hypokalaemia, which was associated with an increased hazard of adverse cardiovascular outcomes. Finerenone reduced the incidence of hypokalaemia. Finerenone reduced the hazard of cardiovascular and arrhythmia outcomes irrespective of serum potassium subgroups. Clinical trials registration: FIDELIO-DKD and FIGARO-DKD are registered with ClinicalTrials.gov, numbers NCT02540993 and NCT02545049, respectively (funded by Bayer AG).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.
- Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, IN 46202, USA.
- Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Charitépl. 1, 10117 Berlin, Germany.
- German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
- Steno Diabetes Center Copenhagen, Herlev 2730, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen DK-2200 , Denmark.
ORCID-Profile: Bertram Pitt, Stefan D Anker, Peter Rossing
Förderung
- Bayer AG
- Fidelity
Zitieren
APA
Pitt, B., Agarwal, R., Anker, S. D., Rossing, P., Ruilope, L., Herzog, C. A., Greenberg, B., Pecoits-Filho, R., Lambelet, M., Lawatscheck, R., Scalise, A., & Filippatos, G. (2025). Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 11(1), 10-19. https://doi.org/10.1093/ehjcvp/pvae074
Vancouver
Pitt B, Agarwal R, Anker SD, Rossing P, Ruilope L, Herzog CA, et al. Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 2025;11(1):10-19. doi:10.1093/ehjcvp/pvae074
BibTeX
@article{Pitt2025,
author = {Pitt, Bertram and Agarwal, Rajiv and Anker, Stefan D and Rossing, Peter and Ruilope, Luis and Herzog, Charles A and Greenberg, Barry and Pecoits-Filho, Roberto and Lambelet, Marc and Lawatscheck, Robert and Scalise, Andrea and Filippatos, Gerasimos},
title = {Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
volume = {11},
number = {1},
pages = {10--19},
doi = {10.1093/ehjcvp/pvae074}
}
EUVIMED